SynAct Pharma AB - Asset Resilience Ratio

Latest as of December 2022: 0.13%

SynAct Pharma AB (SYNACT) has an Asset Resilience Ratio of 0.13% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Skr180.00K

≈ $19.37K USD Cash + Short-term Investments

Total Assets

Skr142.60 Million

≈ $15.35 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2020–2023)

This chart shows how SynAct Pharma AB's Asset Resilience Ratio has changed over time. Check SynAct Pharma AB strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down SynAct Pharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SynAct Pharma AB market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr0.00	0%
Short-term Investments	Skr180.00K	0.13%
Total Liquid Assets	Skr180.00K	0.13%

Asset Resilience Insights

Limited Liquidity: SynAct Pharma AB maintains only 0.13% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

SynAct Pharma AB Industry Peers by Asset Resilience Ratio

Compare SynAct Pharma AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for SynAct Pharma AB (2020–2023)

The table below shows the annual Asset Resilience Ratio data for SynAct Pharma AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	0.04%	Skr93.00K ≈ $10.01K	Skr228.02 Million ≈ $24.54 Million	-0.09pp
2022-12-31	0.13%	Skr180.00K ≈ $19.37K	Skr142.60 Million ≈ $15.35 Million	+1.09pp
2020-12-31	-0.96%	Skr-208.00K ≈ $-22.38K	Skr21.59 Million ≈ $2.32 Million	--

pp = percentage points

About SynAct Pharma AB

ST:SYNACT Sweden Biotechnology

Market Cap

$108.83 Million

Skr1.01 Billion SEK

Market Cap Rank

#18826 Global

#327 in Sweden

Share Price

Skr18.06

Change (1 day)

-1.10%

52-Week Range

Skr10.66 - Skr24.95

All Time High

Skr143.40